Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

JRNYS vs Tablet Health

JRNYS
Graded #88

Higher grade

vs+24.1
Tablet Health
Graded #495

Lower grade

The verdict

JRNYS takes it — 71.7/100 to 47.6/100.

JRNYS grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. JRNYS is a telehealth weight-loss program built around branded GLP-1 medications, including semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), dulaglutide, and liraglutide (Saxenda), paired…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueJRNYS +33
78
45
Dose & formulationJRNYS +19
70
51
Clinical oversightJRNYS +47
84
37
Labs & monitoringJRNYS +11
61
50
FulfillmentJRNYS +8
65
57
Contract termsEven
55
55
JRNYS · left barTablet Health · right bar

The numbers

MetricJRNYSTablet Health
WeighScore71.7/10047.6/100
GradeCC
Scorecard rank#88#495
Semaglutide$89/mo (plus a separate fee, brand-name)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
JRNYS

Graded #88 · C

Strengths

  • Branded GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda)
  • Insured members may pay ~$25/mo for medication after deductible
  • Includes 1-on-1 coaching at every membership tier
  • Led by CMO Dr. Henry Legere with strong academic credentials
  • Transparent membership pricing ($89-$169/mo)

Where it loses points

  • Medication cost separate from membership; self-pay varies
  • Best value requires commercial insurance coverage
  • Compounded option not disclosed; brand-focused
  • State availability not published
Tablet Health

Graded #495 · C

Strengths

  • LegitScript Certified
  • Four named compounding pharmacy partners (Pharmacy Hub, Epiq Scripts, Dr. TelX, Emerad), none with FDA warning letters
  • Oral GLP-1 option for both semaglutide and tirzepatide — uncommon in compounded telehealth
  • Mid-tier pricing starting $179–$299/mo across all four product variants
  • No commitment — cancel anytime

Where it loses points

  • States served not published — you must complete the intake quiz to learn eligibility
  • No founder, CEO, medical director, or pharmacist-in-charge named anywhere
  • No BBB profile found
  • Its Queens NYC pharmacy is 'opening soon' — all dispensing currently routes through external partners
  • FDA issued this company a warning letter dated 19 March 2025; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard